Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active SPMS from the Phase 3 EXPAND Study (4649)

Stanley L. Cohan,Amit Bar-Or,Patricia K. Coyle,Fred D. Lublin,Xiangyi Meng,Wendy Su,Bruce A. C. Cree

Neurology（2021）

引用 0|浏览16

暂无评分

摘要

Assess siponimod efficacy/safety in patients with active SPMS with MS duration (time since first symptom onset) of <16 or ≥16 years (median value) at baseline.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要